The matchup
On October 28, 2026, Eli Lilly shared top-line results from TRANSCEND-T2D-2, a phase 3 trial that put retatrutide directly against Ozempic at its highest approved dose.
The trial followed 1,298 adults with type 2 diabetes for 80 weeks. That is about a year and a half.
The results
People on retatrutide lost an average of 44 to 47 pounds, about 20 to 21 percent of their body weight. People on Ozempic lost about 21 pounds, or 9 percent.
Blood sugar improved more too. A1C, the standard three-month blood sugar number, dropped 2.2 points on retatrutide versus 1.8 on Ozempic.
Lilly also reported bigger improvements in cholesterol, triglycerides and blood pressure.
Why people are excited
Lilly calls this the sixth phase 3 trial where retatrutide delivered. Earlier this year it showed close to 30 percent weight loss over two years in people without diabetes, and in October it made the New England Journal of Medicine for sleep apnea.
Retatrutide works on three hormone targets at once, where Ozempic works on one. This trial is the clearest picture yet of what that extra reach can mean.
When can you get it
Not yet. Lilly plans to file with FDA in the first quarter of 2027. Until it is approved, it cannot legally be sold or compounded, and it is not part of the new HHS peptide pharmacy policy. Our breakdown of that policy: https://thepeptideinstitute.org/news/hhs-peptide-compounding-policy-bpc-157-tb-500/
The fine print
These are top-line numbers from a company press release. The full results have not been published in a journal yet.
Side effects were mostly stomach-related, like nausea, diarrhea and vomiting, at rates similar to Ozempic. More people stopped retatrutide because of side effects, up to about 8 percent on the higher dose versus about 3 percent on Ozempic. Some also reported skin tingling or odd skin sensations.
This is education, not medical advice. Anyone thinking about weight loss medicines should work with a licensed clinician and get bloodwork done.


